Page 10 - Read Online

difference status of the disease as well as on timing. Thus, Financial support and sponsorship
despite the sequencing of different therapies represents a Nil.
true challenge in real life, a standard therapeutic sequence
is still lacking and it is a matter of debate. Conflicts of interest
There are no conflicts of interest.
Therefore novel strategies are needed, especially for
refractory and/or recurrent neuroendocrine neoplasms REFERENCES
that present a poor prognosis. Personalized approaches
are currently being developed and molecular targets are 1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla
emerging. EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred
years after “carcinoid”: epidemiology of and prognostic factors for
Several driver pathways have been investigated and they neuroendocrine tumors in 35,825 cases in the United States. J Clin
may represent important factors in the carcinogenesis 2. Oncol 2008;26:3063-72.
Berardi R, Rinaldi S, Torniai M, Morgese F, Partelli S, Caramanti
process and, therefore, potential targets for new anticancer M, Onofri A, Polenta V, Pagliaretta S, Falconi M, Cascinu S.
therapies. Gastrointestinal neuroendocrine tumors: Searching the optimal
treatment strategy -- A literature review. Crit Rev Oncol Hematol
In particular, activating mutations have been identified 2016;98:264-74.
several genes, including those of the epidermal growth 3. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P,
factor receptor, platelet-derived growth factor receptor, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder
vascular endothelial growth factor, basic-fibroblastic J, Arnold C, Gress T, Arnold R; PROMID Study Group. Placebo-
growth factor, transforming growth factor, insulin-like controlled, double-blind, prospective, randomized study on the
effect of octreotide LAR in the control of tumor growth in patients
growth factor-1, and their receptors, stem cell factor with metastatic neuroendocrine midgut tumors: a report from the
receptor. New drugs (including immunotherapy) and PROMID Study Group. J Clin Oncol 2009;27:4656-63.
several combination regimens with new biological agents 4. Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková
are being developed and studied in recently conducted and E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A,
ongoing trials. Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators.
Lanreotide in metastatic enteropancreatic neuroendocrine tumours.
Further investigations could increase our knowledge about 5. N Engl J Med 2014;371:224-33.
Hardiansyah D, Maass C, Attarwala AA, Müller B, Kletting P,
molecular mechanisms responsible for the neuroendocrine Mottaghy FM, Glatting G. The role of patient-based treatment
neoplasms heterogeneity, about tumor interactions with planning in peptide receptor radionuclide therapy. Eur J Nucl Med
adjacent healthy tissue and as regard its variegated Mol Imaging 2016;43:871-80.
response to treatments, to guarantee the development of 6. Vilar E, Salazar R, Perez-Garcia J, Cortes J, Oberg K, Tabernero J.
new promising therapies. Chemotherapy and role of the proliferation marker Ki-67 in digestive
neuroendocrine tumours. Endocr Relat Cancer 2007;14:221-32.
This special issue on neuroendocrine neoplasms aims to 7. Rindi G, Arnold R, Bosman FT, Capella C, Klimstra DS, Kloppel
summarize the present knowledge about the treatment of G, Komminoth P, Solcia E. Nomenclature and classification of
neuroendocrine neoplasms of the digestive system. In: WHO
these tumors highlighting available evidences as well as Classification of Tumours of the Digestive System, 4th ed, Bosman
new biological perspectives on biological and targeted TF, Carneiro F, Hruban RH, Theise ND (Eds). Lyon: IARC Press;
therapies, also including case reports. 2010. p.13-4.

278
Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ August 17, 2016 ¦